Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
By Dr. Matthew Watson
Company Announcement
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
By Dr. Matthew Watson
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.
Link:
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
Inventiva announces a new Director of the Board of Directors
By Dr. Matthew Watson
Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva’s board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of Sofinnova Partners.
Read more:
Inventiva announces a new Director of the Board of Directors
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
By Dr. Matthew Watson
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
Visit link:
ERYTECH Provides Business and Financial Update for the Third Quarter of 2022
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock
By Dr. Matthew Watson
BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock (the “Offering”). All Shares to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.
More:
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
By Dr. Matthew Watson
PORTLAND, Maine, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2022.
Link:
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
By Dr. Matthew Watson
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene’s board of directors (the “Board”) as an independent director. He will also serve as an audit committee member.
Follow this link:
Adagene Appoints Cuong Do to Board of Directors and Audit Committee
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
By Dr. Matthew Watson
EMERYVILLE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT, will participate in a fireside chat at the Evercore ISI HealthCONx 2022 Conference. The fireside chat will take place on Wednesday, November 30, 2022 at 3:55 p.m. ET.
Go here to read the rest:
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
By Dr. Matthew Watson
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.
Continue reading here:
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
By Dr. Matthew Watson
CAMBRIDGE, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, November 29, 2022, from 10:05-10:25 a.m. ET.
See the rest here:
Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
By Dr. Matthew Watson
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.
More here:
Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference
By Dr. Matthew Watson
FREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.
See the article here:
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
By Dr. Matthew Watson
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast.A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.About NeuroneticsNeuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.Investor Contact:Mark KlausnerWestwicke Partners443-213-0501ir@neuronetics.comMedia Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
See the original post:
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
By Dr. Matthew Watson
BALA CYNWYD, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022. The Company’s presentation will take place on Thursday, December 1, 2022, at 10:10 AM ET.
Read more:
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
By Dr. Matthew Watson
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The discussion will take place on Wednesday, November 30, 2022 at 1:00 p.m. ET (10:00 a.m. PT).
Follow this link:
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
By Dr. Matthew Watson
DURHAM, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022.
Continued here:
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,…
By Dr. Matthew Watson
Award from Leading Life Science Forum Championing Sector Collaboration for Novel Solutions that Address Pressing Health Challenges is the Community’s Highest Honor
See the rest here:
National Public Health Leader Reed Tuckson, MD, Managing Director, Tuckson Health Connections, and Health Innovation Executive Vlad Coric, MD, CEO,...
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
By Dr. Matthew Watson
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced the closing of an underwritten public offering in the United States (the “Offering”) of 641,026 American Depositary Shares (“ADSs”), each representing 180 ordinary shares of Bionomics, at a public offering price of US$7.80 per ADS.
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
By Dr. Matthew Watson
ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that it intends to submit updated labeling to the U.S. Food and Drug Administration (FDA) for its generic version of DaTscan™ (Ioflupane I 123 Injection) to include a new indication and updated safety information. The additional indication will be to assist in the evaluation of adult patients for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging with suspected dementia with Lewy bodies (DLB). Curium intends to match the labeling recently approved by the FDA for GE Healthcare’s DaTscan on November 3, 2022 as generic drugs are required to have the same labeling as the reference listed drug (DaTscan). Curium will update Ioflupane I 123 Injection important risk information to include the new safety information at the time of labeling implementation. Ioflupane I 123 Injection is a SPECT brain imaging agent used to assist in the evaluation of adult patients with suspected Parkinsonian syndromes.
Read the original here:
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
By Dr. Matthew Watson
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year
Go here to see the original:
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update